Oman Pharmaceuticals & Healthcare Report

Providing expert analysis, independent forecasts and competitive intelligence on the pharmaceuticals and healthcare industry.

Report includes: BMI Industry View, Industry SWOT Analysis, Industry Forecasts, BMI's Pharmaceuticals and Healthcare Risk Reward Index, Market Summary, Economic Forecasts, Company Profiles and Competitive Landscape.

Why you should buy this report

  • Benefit from the latest market opportunities
  • Understand the threats to your operations and investments and protect your company against future risks
  • Gain insight on emerging trends that could support, strengthen or disrupt your activities in the market
  • Get a full view of the competitive landscape to assess your market position

Sign up to download the Oman Pharmaceuticals & Healthcare Report

By submitting this form you are acknowledging that you have read and understood our Privacy Policy.

Thank you for your interest

You will shortly receive your free executive summary by email.

Oman Pharmaceuticals & Healthcare Report
Product Price

BMI View: Oman's evolving demographic and epidemiological profile will act as key drivers of growth within the country's pharmaceuticals and healthcare markets over the coming years. We view Oman as having considerable growth potential, supported by an expanding private sector and the government's ongoing commitment to advancing healthcare. The country's weak domestic manufacturing capabilities will ensure Oman remains an import-driven market, particularly as the population favours those innovative medicines sourced from abroad. Over the long term, Oman's population will benefit from more affordable healthcare services as price unification becomes more standardised across the Gulf States.

Headline Expenditure Projections

  • Pharmaceuticals: OMR242mn (USD628mn) in 2015 to OMR258mn (USD671mn) in 2016; 6.8% in local currency and US dollar terms. Forecast in line with Q 2 1 6 .

  • Healthcare: OMR1.10bn (USD2.86bn) in 2015 to OMR1.15bn (USD3.00bn) in 2016; +4.9% in local currency terms, +5.0% in US dollar terms. Forecast in line with Q 2 16 .

Headline Pharmaceuticals & Healthcare Forecasts (Oman 2014-2020)
2014 2015 2016f 2017f 2018f 2019f 2020f
f = BMI forecast. Source: WHO, National Sources, BMI
Pharmaceutical sales, USDbn 0.590 0.630 0.670 0.720 0.770 0.820 0.880
Pharmaceutical sales, % of GDP 0.72 0.86 0.89 0.92 0.94 0.95 0.96
Pharmaceutical sales, % of health expenditure 20.6 21.0 21.3 21.7 22.2 22.6 23.1
Health spending, USDbn 2.860 3.000 3.150 3.300 3.460 3.630 3.800

Risk/Reward Index

In our Q316 Pharmaceutical Risk/Reward Index (RRI) Oman's score of 47.6 out of 100 is marginally lower than its score last quarter of 48.8, moving down one position to 10th place out of 31 countries analysed in the whole Middle East and Africa (MEA) region. Regionally, Oman ranks relatively poorly compared to the other Gulf States - only Iraq is positioned lower. Oman has limited longer-term commercial potential due to its small population, low per capita spending on pharmaceuticals and the fact that the government is responsible for the bulk of healthcare costs, which will increase the need for cost containment in the coming years. However, Oman's well-established intellectual property regime and exemplary business environment will boost Oman's attractiveness as an investment destination.

Latest Updates

  • In May 2016, as part of a national plan to tackle antibiotic resistance, a national campaign to define the rational use of antibiotics was launched by the Omani Ministry of Health.

  • In April 2016, Oman's Health Minister, Ahmad Al Saidi, reported that over 390 doctors in Oman had resigned in 2015 as a result of failed delivery on a number of health projects.

  • In April 2016, over 50 Omani hospitals and clinics took part in the International Health and Medical Treatment exhibition - with representatives from India, Thailand, Korea, Iran, Turkey, Germany, Ukraine, Cuba and the UAE present - supporting medical tourism in Oman.

BMI Economic View

Tightening liquidity conditions, public spending cuts, and weak export growth will present headwinds for Oman's economy and corporate sector over 2016. Growth will weaken to 2.3% in real terms, and 2.5% in 2017, compared to the annualised rate of 4.0% recorded between 2010 and 2014.

BMI Political View

Royal succession is the major question regarding Oman's political future, although demographic change and regional instability also pose challenges. In particular, the escalating tensions between Iran and Saudi Arabia threaten to undermine Oman's long-held position of regional neutrality. The impetus for any major political change is likely to come from Sultan Qaboos bin Said al-Said, assuming that he tackles the issue before the end of his reign.

BMI Industry View
Table: Headline Pharmaceuticals & Healthcare Forecasts (Oman 2014-2020)
Industry Forecast
Pharmaceutical Market Forecast
Table: Pharmaceutical Sales, Historical Data And Forecasts (Oman 2012-2020)
Healthcare Market Forecast
Table: Healthcare Expenditure Trends, Historical Data And Forecasts (Oman 2012-2020)
Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (Oman 2012-2020)
Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (Oman 2012-2020)
Prescription Drug Market Forecast
Table: Prescription Drug Market Indicators, Historical Data And Forecasts (Oman 2012-2020)
Patented Drug Market Forecast
Table: Patented Drug Market Indicators, Historical Data And Forecasts (Oman 2012-2020)
Generic Drug Market Forecast
Table: Generic Drug Market Indicators, Historical Data And Forecasts (Oman 2012-2020)
OTC Medicine Market Forecast
Table: Over-The-Counter (OTC) Medicine Market Indicators, Historical Data And Forecasts (Oman 2012-2020)
Pharmaceutical Trade Forecast
Table: Pharmaceutical Trade Data And Forecasts (Oman 2014-2020)
Table: Pharmaceutical Trade Data And Forecasts local currency (Oman 2014-2020)
Industry Risk/Reward Index
Middle East and Africa Risk/Reward Index - Q3 2016
Oman Risk/Reward Index
Regulatory Review
Intellectual Property Issues
Pricing Regime
Reimbursement Regime
Market Overview
Healthcare Sector
Table: Healthcare Resources (Oman 2010-2015)
Table: Healthcare Personnel (Oman 2010-2015)
Table: Healthcare Activity (Oman 2010-2015)
Research & Development
Clinical Trials
Competitive Landscape
Research-Based Industry
Table: Multinational Market Activity
Generic Drugmakers
Pharmaceutical Distribution
Pharmaceutical Retail Sector
Company Profile
National Pharmaceutical Industries
Zynova/Oman Pharmaceutical Products Company
Demographic Forecast
Table: Population Headline Indicators (Oman 1990-2025)
Table: Key Population Ratios (Oman 1990-2025)
Table: Urban/Rural Population & Life Expectancy (Oman 1990-2025)
Table: Population By Age Group (Oman 1990-2025)
Table: Population By Age Group % (Oman 1990-2025)
Pharmaceutical Expenditure Forecast Model
Healthcare Expenditure Forecast Model
Notes On Methodology
Risk/Reward Index Methodology
Index Overview
Table: Pharmaceutical Risk/Reward Index Indicators
Indicator Weightings

The Oman Pharmaceuticals & Healthcare Report features BMI Research's forecasts for drugs and healthcare expenditure and imports and exports, focusing on the growth outlook for the prescription, OTC, patented drugs and generics market segments.

BMI's Oman Pharmaceuticals & Healthcare Report provides industry professionals, strategists, company executives, investors, analysts and sales/marketing heads with independent forecasts and competitive intelligence on the Oman pharmaceutical and healthcare industry.

Key Benefits

  • Benchmark BMI's pharmaceutical and healthcare market forecasts for Oman, to test other views - a key input for successful budgeting and strategic business planning in the Omani pharmaceutical and healthcare market.
  • Target business opportunities and risks in the Omani pharmaceutical and healthcare sector through our reviews of latest industry trends, regulatory changes and major deals, projects and investments in Oman.
  • Assess the activities, strategy and market position of your competitors using our company profiles (including SWOTs, KPIs and latest activity) and competitive landscape tables.


BMI Industry View

An at-a-glance perspective on the latest regulatory developments, key forecast indicators and major corporate developments, covering the prescription, OTC and generics markets. The pharmaceuticals and healthcare SWOT outlines strategic factors that affect the basic assumptions underpinning BMI’s forecast analysis, and taken together with BMI’s political, economic and business environment SWOTs, it gives a complete overview of market climate.

BMI Industry Forecast Scenario

Industry forecasts to end-2019 for all key indicators, supported by explicit assumptions, plus analysis of key downside risks to the main forecasts:

  • Healthcare: Total healthcare expenditure (USDbn), healthcare expenditure (% of GDP), healthcare expenditure per capita (USD), hospital beds, doctors, and birth & mortality rates (all per ‘000 population).
  • Pharmaceutical Market: Drug expenditure in USDbn, % of GDP and per capita (USD).
  • Patented Drug Market: Prescription drug sales (USDbn & % of total sales).
  • Generic Drug Market: Generic product sales (USDbn), generic sales (% of total sales).
  • OTC Drug Market: OTC sales (USDbn & % of total sales).
  • Macroeconomic Forecasts: Nominal and real GDP, % real GDP growth, % private consumption growth, % industrial output growth, % consumer price index, % GDP price deflator, exports, imports, trade balance, current account balance, foreign direct investment, exchange rate against USD, government expenditure and external debt.

BMI’s Pharmaceuticals and Healthcare Risk Reward Index

BMI’s Risk Reward Index provides investors (both national and multinational) looking for opportunities in the region with a clear country-comparative assessment of the market’s risks and potential rewards. Each of the country markets are scored using a sophisticated model that includes more than 40 industry, economic and demographic data points to provide indices of highest to lowest appeal to investors, with each position explained.

Market Summary

A snapshot of key market characteristics, including total size of the pharmaceuticals and healthcare segments, growth drivers, leading therapeutic areas and the competitive landscape

Industry Developments

A focus on government healthcare reforms, epidemiological trends, mergers and acquisitions, product launches, market entries, FDI activity, R&D, biotechnology, clinical trials and supply chain issues.

Regulatory Regime

Details of the industry regulatory framework and key legislation covering the licensing of new products/services, pricing and reimbursements, intellectual property, taxation and advertising, as well as analysis of the overall regulatory burden.

Competitive Landscape

The competitive landscape section provides comparative company analyses and index by USD sales and % share of total sales – for the total pharmaceutical sector, as well as the OTC, generics and distribution sub-sectors.

Company Profiles*

Examines the competitive positioning and short- to medium-term business strategies of key industry players. Strategy is examined within the context of BMI’s industry forecasts, our macroeconomic views and our understanding of the wider competitive landscape to generate Company SWOT analyses. The latest financial and operating statistics and key company developments are also incorporated within the company profiles, enabling a full evaluation of recent company performance and future growth prospects.

*Company profiles are not available for every country. Those reports instead contain information on the current activities of prominent companies operating in the market.